137 related articles for article (PubMed ID: 11782867)
21. Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats.
Mori A; Lee P; Yamashita T; Nishimaki Y; Oda H; Saeki K; Miki Y; Mizutani H; Ishioka K; Honjo T; Arai T; Sako T
Vet Res Commun; 2009 Dec; 33(8):957-70. PubMed ID: 19728131
[TBL] [Abstract][Full Text] [Related]
22. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Gribble FM; Manley SE; Levy JC
Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
[TBL] [Abstract][Full Text] [Related]
23. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
24. Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days.
Mori Y; Mamori S; Tajima N
Diabetes Obes Metab; 2005 Mar; 7(2):182-8. PubMed ID: 15715891
[TBL] [Abstract][Full Text] [Related]
25. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
[TBL] [Abstract][Full Text] [Related]
26. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
[TBL] [Abstract][Full Text] [Related]
27. Improvement of insulin resistance by a new insulin secretagogue, nateglinide--analysis based on the homeostasis model.
Shiba T
Diabetes Res Clin Pract; 2003 Nov; 62(2):87-94. PubMed ID: 14581145
[TBL] [Abstract][Full Text] [Related]
28. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Luzio SD; Anderson DM; Owens DR
J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
[TBL] [Abstract][Full Text] [Related]
29. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
[TBL] [Abstract][Full Text] [Related]
30. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
31. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
Mine T; Miura K; Kitahara Y; Okano A; Kawamori R
Biol Pharm Bull; 2002 Nov; 25(11):1412-6. PubMed ID: 12419950
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
[TBL] [Abstract][Full Text] [Related]
33. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
[TBL] [Abstract][Full Text] [Related]
34. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
Mari A; Gastaldelli A; Foley JE; Pratley RE; Ferrannini E
Diabetes Care; 2005 May; 28(5):1132-8. PubMed ID: 15855578
[TBL] [Abstract][Full Text] [Related]
35. Postprandial interstitial insulin concentrations in type 2 diabetes relatives.
Sandqvist M; Johanson EH; Ahrén B; Axelsen M; Schmelz M; Smith U; Jansson PA
Eur J Clin Invest; 2006 Jun; 36(6):383-8. PubMed ID: 16684121
[TBL] [Abstract][Full Text] [Related]
36. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.
Mori Y; Ojima K; Fuujimori Y; Aoyagi I; Kusama H; Yamazaki Y; Kojima M; Shibata N; Itoh Y; Tajima N
Endocrine; 2006 Apr; 29(2):309-15. PubMed ID: 16785606
[TBL] [Abstract][Full Text] [Related]
37. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
Li J; Tian H; Li Q; Wang N; Wu T; Liu Y; Ni Z; Yu H; Liang J; Luo R; Li Y; Huang L
Diabetes Obes Metab; 2007 Jul; 9(4):558-65. PubMed ID: 17587398
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
[TBL] [Abstract][Full Text] [Related]
39. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
[TBL] [Abstract][Full Text] [Related]
40. Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism.
Dimitriadis G; Boutati E; Lambadiari V; Mitrou P; Maratou E; Brunel P; Raptis SA
Eur J Clin Invest; 2004 Jul; 34(7):490-7. PubMed ID: 15255786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
